Navigation Links
BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
Date:5/20/2008

in estimates that PEG-PAL could be a potential treatment option for a significant portion of the PKU population.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of its product candidate PEG-PAL, and expectations regarding filings with regulatory agencies. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results of current and planned clinical trials re
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Announces FDA Approval for Kuvan
2. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
3. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
4. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
5. Go Healthy Initiates Additional Clinical Tests on Cholesterade
6. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
7. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
8. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
9. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
10. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
11. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... that results in demyelination, axonal transection, and neurodegeneration. The ... by the immune system, which targets neurons within the ... disease in which the damage of the myelin sheath ...
(Date:8/29/2014)... , Aug. 29, 2014  Pacific Medical Data Solutions ... new website design . The main website, along with ... the company,s new services and content relevant to the ... new streamlined design, viewers can now better understand how ... care practices and create a more visible platform about ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Soft Tissue Repair Devices Market 2014-2018" report to ... the mass of cells that connect, support, or surround ... such as tendons, ligaments, cartilage, fascia, and other fibrous ... these tissues with age result in wear and tear ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3PMDS Announces New Website 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
... Feb. 24 Biopharmaceutical manufacturers, responsible ... recombinant proteins, monoclonal antibodies, and vaccines -- are ... the type of product being assessed. A ... routine sampling and testing requirements associated with the ...
... Kensey Nash Corporation (Nasdaq: KNSY ) announced ... (IDE) application to the U.S. Food and Drug Administration ... biomaterials technology for treating articular cartilage defects of the ... Repair Device, which consists of a proprietary bi-phasic, bioresorbable ...
Cached Medicine Technology:White Paper Explains Aspects of Testing From Purified Bulk Drug Substance to Sterile Liquid Final Drug Product 2Kensey Nash Announces IDE Submission for Cartilage Repair Device 2Kensey Nash Announces IDE Submission for Cartilage Repair Device 3Kensey Nash Announces IDE Submission for Cartilage Repair Device 4
(Date:8/29/2014)... across the Arabian Peninsula and spread to Europe several ... of several hundred people since its discovery in 2012. ... how easily the pathogen spreads from human to human. ... the University of Bonn have now come to the ... transmission is low. Still, a third of infected persons ...
(Date:8/29/2014)... Glendale Botox experts at Glenoaks Laser Center are ... of September. This special offer features 10 free units of ... can take advantage of this special offer to completely transform ... work with patients to determine if Botox or Juvederm is ... , Botox is a treatment made from the botulinum toxin. ...
(Date:8/29/2014)... VHA Central Atlantic recognized Novant Health ... honoring nine facilities for meeting or exceeding national performance ... Health, providing quality, affordable healthcare for our communities has ... executive vice president and chief medical officer. “These awards ... for each and every one of our patients.” , ...
(Date:8/29/2014)... TX (PRWEB) August 29, 2014 PreDiabetes ... off the fall season by offering Web shoppers a 20% ... PreD Store , the Company’s online healthy living shop, beginning ... should be top priority when heading into the chilly fall ... lifestyle habits. During this season, people usually ditch the healthy ...
(Date:8/29/2014)... August 29, 2014 Many Americans are ... keep diabetes type 2 at bay, patients should consider ... make the necessary lifestyle changes. While some diabetes risk ... history, advanced age, or belonging to certain ethnic groups, ... – their weight. Carrying extra pounds, especially in the ...
Breaking Medicine News(10 mins):Health News:MERS: Low transmissibility, dangerous illness 2Health News:MERS: Low transmissibility, dangerous illness 3Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Novant Health Recognized for Excellence in Clinical Care 2Health News:Novant Health Recognized for Excellence in Clinical Care 3Health News:PreDiabetes Centers Online Store Launches Fall Savings Event 2Health News:Diet Doc Announces Specialized Diet Plans that Help Patients Prevent Diabetes by Stabilizing Blood Sugar Levels and Losing Excess Fat 2Health News:Diet Doc Announces Specialized Diet Plans that Help Patients Prevent Diabetes by Stabilizing Blood Sugar Levels and Losing Excess Fat 3
... has led to the development of proposals to dump about 800 ... end of the month. ,The move follows the ... six months should stay on a list. ,Patients ... within six months are referred back to their GP for monitoring. ...
... have identified key compounds that stimulate stem cell growth ... is set to appear in the September 2006 issue ... one day lead to restored function for people who ... sclerosis, and a wide range of neurological disorders. The ...
... doctors in North Karnataka, cautioned by the health and ... and not to harass them. // ,The ... take action against doctors harassing and denying treatment to ... of the first anniversary celebration of ‘Ashodaya’, which is ...
... to launch a new vaccination project to protect ... vaccination against pneumococcal meningitis will also be integrated ... meningitis is very serious," Diane McConnell, manager of ... die or be left with very severe after ...
... nitrogen-containing compounds that food producers use to cure meats may ... says a new study. // ,Previous studies have found ... study by Graham Barr at Columbia University Medical Center in ... the affect on lung function in humans, reported the online ...
... Mukesh Haikerwal, today urged all Australians to think about ... desire to donate organs.// ,Research published in the ... for transplant are harvested from only a fraction of ... found that, in many instances, organs are not donated ...
Cached Medicine News:Health News:800 Patients to be Dumped from Hospital Waiting Lists 2Health News:Action Against Doctors Harassing HIV/AIDS Patients 2Health News:AMA Urges Organ Donors to Speak Up 2
... Dehydroepiandrosterone sulfate (DHEA-S) is the sulfate ... and by enzymatic conversion of DHEA in ... major C19 steroid secreted by the adrenal ... and estrogen biosynthesis. DHEA possesses relatively weak ...
... Dehydroepiandrosterone sulfate (DHEA-S) is the sulfate ... and by enzymatic conversion of DHEA in ... major C19 steroid secreted by the adrenal ... and estrogen biosynthesis. DHEA possesses relatively weak ...
... sulfate ester of DHEA, derived from sulfated ... in adrenal and extradrenal tissues. DHEA is ... adrenal cortex, and is a precursor for ... weak androgenic activity, which for unsulfated DHEA ...
... kit is based on the competition principle ... of DHEA-S present in the sample and ... horse-radish peroxidase compete for the binding sites ... the wells. After one hour incubation the ...
Medicine Products: